logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Celldex Therapeutics, Inc.

CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā€¦ read more

Healthcare

Biotechnology

39 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$25.60

Price

+1.23%

$0.31

$25.29

Previous Close

$25.42

Open

Premium

52w Discount
Market Cap

$1.701b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$2.600m

-63.0%

1y CAGR

+43.7%

3y CAGR

+20.4%

5y CAGR
Earnings

-$224.532m

-42.2%

1y CAGR

-26.6%

3y CAGR

-34.8%

5y CAGR
EPS

-$3.38

-38.0%

1y CAGR

-14.5%

3y CAGR

-22.5%

5y CAGR
Book Value

$598.363m

$648.439m

Assets

$50.076m

Liabilities

$2.621m

Debt
Debt to Assets

0.4%

-

Debt to EBITDA
Free Cash Flow

-$181.670m

-13.8%

1y CAGR

-21.2%

3y CAGR

-33.3%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.